



Investor Fact Sheet

Financial key figures 2024/25

(Audited Swiss GAAP FER figures)

in thousand CHF

	2024/25	in %	2023/24	in %	Change	in %
Sales of goods and services group	748 866	100.0 %	548 457	100.0 %	200 410	36.5 %
thereof continuing business group	501 203	66.9 %	385 152	70.2 %	116 051	30.1 %
Ypsomed Delivery Systems (YDS)	501 203	66.9 %	385 152	70.2 %	116 051	30.1 %
Ypsomed Diabetes Care (YDC)	236 870	31.6 %	151 049	27.5 %	85 821	56.8 %
Others	10 856	1.4 %	12 255	2.2 %	-1 399	-11.4 %
Gross profit	292 066	39.0 %	219 530	40.0 %	72 536	33.0 %
Operating profit group	112 851	15.1 %	86 219	15.7 %	26 631	30.9 %


Financial income	3 675	0.5 %	4 835	0.9 %	-1 184	-24.5 %
Financial expenses	-12 211	-1.6 %	-9 183	-1.7 %	-3 004	32.7 %
Income taxes	-16 810	-2.2 %	-3 506	-0.6 %	-13 305	379.5 %
Net profit	87 504	11.7 %	78 366	14.3 %	9 138	11.7 %

Earnings per share diluted in CHF	6.41		5.74		0.67	11.6 %
Earnings per share undiluted in CHF	6.41		5.74		0.67	11.7 %


Operating profit	112 851	15.1 %	86 219	15.7 %	26 631	30.9 %
Depreciation and impairment of fixed assets	64 338		43 547		20 790	47.7 %
Amortisation and impairment of intangible assets	41 013		31 319		9 694	31.0 %
EBITDA (Operating profit before depreciation and amortisation)	218 201	29.1 %	161 085	29.4 %	57 116	35.5 %

Equity ratio in %	51.1 %		56.1 %		-5.0 %	
Investments in fixed assets	202 597		120 565		82 032	68.0 %
Investments in intangible assets	69 672		79 893		-10 222	-12.8 %
Number of employees	2 753		2 389		364	15.2 %
Number of full-time positions	2 644		2 296		349	15.2 %

Sales at group level



EBIT at group level



Further information on significant shareholders and shareholder groups as well as other financial figures of the Ypsomed Group can be found in the Annual Report 2024/25 and at www.ypsomed.ch.

Legal disclaimer: The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG, its advisors or representatives, nor their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as “may”, “plans”, “expects”, “believes” and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.